A phase I study of lenalidomide in patients with chronic myelomonocytic leukemia (CMML) - AGMT_CMML-1.

about

A phase I study of lenalidomide in patients with chronic myelomonocytic leukemia (CMML) - AGMT_CMML-1.

Item

http://www.wikidata.org/entity/Q38602492

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

A phase I study of lenalidomid ...... leukemia (CMML) - AGMT_CMML-1.

@en

type

Item

label

A phase I study of lenalidomid ...... leukemia (CMML) - AGMT_CMML-1.

@en

prefLabel

A phase I study of lenalidomid ...... leukemia (CMML) - AGMT_CMML-1.

@en

P1476

A phase I study of lenalidomid ...... leukemia (CMML) - AGMT_CMML-1.

@en

P2093

Andreas Petzer

http://www.w3.org/2001/XMLSchema#string

Beate Mayrbaeurl

http://www.w3.org/2001/XMLSchema#string

Josef Thaler

http://www.w3.org/2001/XMLSchema#string

Reinhard Stauder

http://www.w3.org/2001/XMLSchema#string

Richard Greil

http://www.w3.org/2001/XMLSchema#string

Sigrid Machherndl-Spandl

http://www.w3.org/2001/XMLSchema#string

Sonja Burgstaller

http://www.w3.org/2001/XMLSchema#string

Thomas Kuehr

http://www.w3.org/2001/XMLSchema#string

Thomas Noesslinger

http://www.w3.org/2001/XMLSchema#string

P2860

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

Proposals for the classification of the myelodysplastic syndromes

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.

Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q.

Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System

A Multi-Institution Phase I Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia (CMML)

A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia.

Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B.

P304

1121-1126

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/10428194.2017.1369070

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Peter Valent

Alois Lang

P577

2017-08-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28853315

http://www.w3.org/2001/XMLSchema#string